Another study linking long term GC and CV risk in RA! Medicare data >65yo 130000+ pts 1-year incidence CV ⬆️ as follows: 📍Dose ≤5mg 1.4% 📍Dose 5-10mg 1.7% 📍Dose >10mg 1.9% Not replicated in younger pts (Optum data) #ACR21 #Abst1915 @RheumNow https://t.co/DLXdfvfiBW

Abst 1916 England & colleagues determined if anti-MAA Ab = predictor of incident RA-ILD - Anti-MAA Ab significantly associated w/ incident RA-ILD - Strongly associated w/ higher concentrations anti-MAA - Antibody associations = antigen/isotype dependent #ACR21 @RheumNow https://t.co/z1RspmxBvc https://t.co/hvUm4O6RmX

• Akhil Sood MD on Twitter: "Abst 0281 England & colleagues used unsuper…

DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid disease properly is the current best strategy for treating RA-ILD. Abstr#1918 #ACR21 @RheumNow #ACRBest https://t.co/FpUK6upyOi

Is there a relationship between the weather and RA disease activity?⛈️ #ACR21 Abs#1912 🌡️Temperature & humidity significantly affect pain, TJC & SJC 🌦️PGA was mostly influenced by humidity Should we take the weather into account when assessing patients? @RheumNow https://t.co/e3PewZWkLR

RA ILD survival. The ‘smoking’ gun! RA ILD in VA pts mostly menand smokers - data showed disease activity of #RheumatoidArthritis & ⬆️HAQ both reduced survival independently #ACRBest #ACR21 abst#1918 @RheumNow https://t.co/8GD7rHV07t

Preventive Window of Opportunity in RA? Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract #0455 presented at the #ACR21 annual meeting. https://t.co/bCN1k5hhUc https://t.co/gpEHk0XIRc

• https://bit.ly/3EYTFwu

Can we predict who will develop #RA-ILD? Perhaps anti-MAA is the answer! #ACR21 Abs#1916 👉🏼⬆️anti-MAA antibody assoc with incident ILD risk 👉🏼Associations are antigen & isotype dependent 👉🏼Antibody measurement may be useful to risk stratify for RA-ILD @RheumNow https://t.co/nC0OkuWtGU

Once again #steroids are bad in #RheumatoidArthritis from 2 large admin databases in age >65 in Medicare data, not in younger pts -Optum data. Clear dose response #ACR21 #ACRBest @RheumNow abst#1915 https://t.co/XL93jty7C9

HCQ adherence (>90%) associated with 52% reduced cardiovascular mortality in RA and SLE. Seen for MI, stroke, not VTE. Abstr#1909 #ACR21 @RheumNow https://t.co/5UncmqZVNp

Claims data looked at 21,114 #RA & #SLE pts - 4.3% had CV Death. The risk of CVD was worse w/ HCQ nonadherence (HR 1.08; 0.91-1.31) and better w/ HCQ adherence (HR 0.51;0.42-.66) HCQ nonadherence shows higher CV mortality #ACR21 Abst# 1909 https://t.co/di1mBliMN6

Dementia is ⬆️in #RheumatoidArthritis says Elena Myasoedva but #RA has more DM &CV disease which ⬆️dementia. Need to separate vascular dementia from Alzheimer’s. When I trained we thought less dementia in RA -likely not true. More work is coming. 9T213 aging hub #ACR21 @RheumNow

Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept: ⭐️Seropositivity ⭐️no prior bMDARD use ⭐️low HAQ-DI ⭐️low BMI Abst#1228 #ACR21 @Rheumnow https://t.co/NvJoSWScZs